Hematology

Test projects which agent will work best against particular tumors.

Treatment advances have caused significant progress in survivorship.

Treatment utilizes immune cells grown from patient bone marrow to treat multiple myeloma.

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Excess medical expenses, employment disability, and a drop in production at work common in cancer survivors.

Study warns that drug reviewers don't look at long term survival of patients.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses changes in store for the care of cancer patients over the next decade.

Mass spectrometry reveals all proteins that repair damaged cancer DNA.

Genetically determined telomere length may not influence mortality.

AbbVie, Roche, and Genentech are collectively developing the drug to treat relapsed or refractory CLL patients with the 17p deletion genetic mutation.

Highest uninsured rates found in patients with testicular, stomach, and cervical cancers.

Taking over-the-counter supplements beyond the recommended amount could increase cancer risk.

Re-engineering antibodies allows them to selectively kill tumors.

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

Mild cognitive impairment can set in prior to the start of therapy.

Mortality gap in cancer deaths among African Americans and Caucasians may eventually disappear.

Treatment will be available for clinical trials in patients with certain types of leukemia and non-Hodgkin lymphomas later this year.

The FDA is considering approval for a liquid bendamustine hydrochloride rapid infusion product.

Longer telomeres gives cancer cells a survival advantage.

Ibrutinib found to control Waldenstrom's Macroglobulinemia in 95% of patients.

Enzyme blocker reduces growth of intestinal tumors.

Private insurers and Medicare patients can pay up to 43 times less than the uninsured.

Drug could eventually also treat prostate cancer.